CTT Systems

CTT Systems

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

CTT Systems - Remain seated for another quarter

29 april 2026

  • 2026 now also clouded by uncertainty
  • '26e-'27e EBIT down 12-4%; ~60% EBIT CAGR '25-'28e
  • 20-11x EBIT '26e-'27e, ~25-40% ROCE, net cash

Better OEM activity, uncertain flight traffic

2026 started well for CTT, with 41% organic growth (ABGSCe +29%), sequential growth in both OEM and aftermarket (AM) sales, and normalised inventories among distributors. Key drivers for CTT are the increase in aircraft production rates and higher content per aircraft. Both of these factors are now materialising, which should drive >70% organic growth y-o-y in OEM sales for the upcoming quarters, and ~55% growth FY'26. However, flight cancellations due to the Middle Eastern conflict will likely hurt AM sales . Global traffic remained stable y-o-y in April, and CTT's products are mainly on the most fuel efficient and profitable (long-haul) aircraft, but CTT still views this as a risk, which is why we forecast declining earnings again in Q2, before a return to >40% growth from Q3. Our view for 2027-2028 remains largely intact on the back of 1) higher production rates, 2) increased penetration and 3) growth in the installed base.

Return to earnings growth in Q3'26e

We lower '26e EBIT by 12% to factor in an AM business that is affected by flight cancellations, and a slower OEM ramp-up. Our '27e EBIT is down only 4% though, as we believe the visibility from increased production rates, a rebound in air travel and postponed VIP sales should still support solid earnings. This should in turn drive a ~35% organic sales CAGR and a ~60% EBIT CAGR in '25-'28e.

Multi-year double-digit growth potential

Despite seeing tougher headwinds than we had previously anticipated, CTT's core strengths remain: the company benefits from a near-monopolistic position, strong demand, and its margin-accretive AM business. This should drive long-term double-digit earnings growth, while the share is now trading at 20-11x EBIT '26e-'27e (23x L10Y), offering 3-6% dividend yields and ~25-40% ROCE.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-07-15 Svedbergs Group - Logistics drag persists into H2 Svedbergs G.. Analys
2026-07-15 Infrea - Strong quarter but pegged to Netel Infrea Analys
2026-07-15 Coor - Solid earnings despite softer sales Coor Analys
2026-07-15 Svedbergs Group - Nordics and one-offs weigh Svedbergs G.. Analys
2026-07-14 Nexam Chemical - Solid Q2, profitability within r... Nexam Chemical Analys
2026-07-14 Nexam Chemical - Record sales and first positive ... Nexam Chemical Analys
2026-07-14 Eastnine - Warsaw to become the largest market Eastnine Analys
2026-07-13 Ascelia Pharma - CRL update Ascelia Pharma Analys
2026-07-13 Medicover - Steady as she goes Medicover Analys
2026-07-13 Arctic Paper - Pulp beats paper Arctic Paper Analys
2026-07-13 Studsvik - Gearing up for the new-build era Studsvik Analys
2026-07-10 StrongPoint - The American dream StrongPoint Analys
2026-07-10 Careium - The pressure valve starting to open Careium Analys
2026-07-10 StrongPoint - Solid Q2 performance StrongPoint Analys
2026-07-10 Careium - Growth's comeback tour continues Careium Analys
2026-07-09 Infrea - Road tripping with Netel Infrea Analys
2026-07-08 Alligo - Softer growth, but margin recovery conti... Alligo Analys
2026-07-08 Qliro - Key earnings drivers intact Qliro Analys
2026-07-07 Nexam Chemical - We expect a firmer sequential qu... Nexam Chemical Analys
2026-07-07 Eastnine - Adding in Warsaw Eastnine Analys